<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597697</url>
  </required_header>
  <id_info>
    <org_study_id>NN1436-4570</org_study_id>
    <nct_id>NCT04597697</nct_id>
  </id_info>
  <brief_title>A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease</brief_title>
  <official_title>A Trial Investigating the Pharmacokinetic Properties of Insulin Icodec in Subjects With Various Degrees of Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants will receive one insulin icodec dose, which will be administered in the morning&#xD;
      of the day of dosing.&#xD;
&#xD;
      The study will last for about 8 weeks. Participants will have 8 visits with the study doctor&#xD;
      in the clinical research unit.&#xD;
&#xD;
      Insulin icodec will be injected into a skin fold with a small needle (subcutaneous&#xD;
      application) using a pen injector prefilled with a volume of 3 mL (about a spoonful).&#xD;
&#xD;
      Participants must not participate if they meet certain conditions called exclusion criteria,&#xD;
      such as an age of below 18 years or above 70 years, if participants are over- or underweight,&#xD;
      using certain medicines, or have serious health conditions (other than impaired liver&#xD;
      function ).&#xD;
&#xD;
      Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the&#xD;
      study period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 7, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC,Ico,0-inf,SD, Area under the serum insulin icodec concentration-time curve after a single dose</measure>
    <time_frame>Day 1</time_frame>
    <description>From 0 hours until infinity after trial product administration (pmol*h/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax,Ico,SD, Maximum observed serum insulin icodec concentration after a single dose</measure>
    <time_frame>Day 1</time_frame>
    <description>From 0 hours until last measurement time after trial product administration (pmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,Ico,SD, Time to maximum observed serum insulin icodec concentration after a single dose</measure>
    <time_frame>Day 1</time_frame>
    <description>From 0 hours until last measurement time after trial product administration (hours)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Subjects with normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with mild hepatic impairment, child-pugh grade A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with moderate hepatic impairment, child-pugh grade B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with severe hepatic impairment, child-pugh grade C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will be allocated into four groups. Receiving one insulin icodec dose, administered subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin icodec</intervention_name>
    <description>Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.</description>
    <arm_group_label>Subjects with mild hepatic impairment, child-pugh grade A</arm_group_label>
    <arm_group_label>Subjects with moderate hepatic impairment, child-pugh grade B</arm_group_label>
    <arm_group_label>Subjects with normal hepatic function</arm_group_label>
    <arm_group_label>Subjects with severe hepatic impairment, child-pugh grade C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Aged 18-70 years (both inclusive) at the time of signing informed consent&#xD;
&#xD;
          -  Body mass index between 18.5 and 39.9 kg/m^2 (both inclusive) Specific inclusion&#xD;
             criterion only for subjects with hepatic impairment&#xD;
&#xD;
          -  Subjects with stable hepatic impairment classified as Child-Pugh grade A, B or C as&#xD;
             assessed by the investigator. Stable hepatic impairment is defined as no clinically&#xD;
             significant change in disease status, as judged by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial product or related products&#xD;
&#xD;
          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of&#xD;
             child-bearing potential and not using an adequate contraceptive method (adequate&#xD;
             contraceptive measures as required by local regulation or practice)&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Praha 7</city>
        <zip>17000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>83101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

